BHC - Bausch Health gains after an appeals hearing in Norwich case over generic Xifaxan
2024-01-08 13:53:28 ET
More on Bausch Health Companies
- Bausch Health: $20bn Debt Is A Mighty Elephant In The Room
- Bausch Health Companies Inc. (BHC) Q3 2023 Earnings Call Transcript
- Bausch Health Companies Inc. 2023 Q3 - Results - Earnings Call Presentation
- Bausch + Lomb wins FDA nod for eye surgery product
- Bausch reports positive Phase 2 data for ulcerative colitis drug
For further details see:
Bausch Health gains after an appeals hearing in Norwich case over generic Xifaxan